Loading…
Develops precision neuroscience drugs targeting receptor-associated proteins for epilepsy and neurological pain.
Develops precision neuroscience drugs targeting receptor-associated proteins for epilepsy and neurological pain.
Has no product on sale, so it funds trials with capital raised from investors, including a 2024 stock-market debut. Any revenue would start with approval of its lead epilepsy drug, or earlier from a licensing deal with a larger drugmaker.
Moat: none (IP / patents). Novel receptor-associated-protein targeting approach spun from prior pharma research, but still clinical-stage.
Headquarters: Boston, Massachusetts, US · Founded: 2022 · Employees: 84
Size Rapport Therapeutics (RAPP) is a United States Health Care company (Biotechnology) with a market value of $1.17B, the 2150th largest of 3,117 United States companies the cockpit tracks. Shares closed at $24.44 on 6 Nov 2026.
Performance Over six months the shares fell 35.8%, against -10.4% for the median peer and -1.1% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth The operating margin is -838.1% (peer median -7.4%).
Valuation It trades at 39.3× enterprise value to sales against a peer median of 6.3× (2nd most expensive of 16).
Short interest Short interest is 6.4% of the free float (15 Oct 2026).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $20.0M | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $19.1M | -$1.02M | -$839,000 | -$112,000 | -$15,000 |
| EBITDA | -$167M | -$124M | -$82.2M | -$36.1M | -$10.4M |
| Net income | -$150M | -$111M | -$78.3M | -$34.8M | -$10.7M |
| Free cash flow | -$121M | -$88.1M | -$67.2M | -$28.8M | -$3.53M |
| Capital expenditure | $333,000 | $616,000 | $2.40M | $1.64M | $284,000 |
| Total debt | $9.39M | $11.5M | $1.48M | $2.15M | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Rapport Therapeutics RAPP | $1.17B | -36% | n/a | -838% | 39.3× | n/a |
| Xenon Pharmaceuticals XENE | $3.79B | +4% | -100% | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RAPP | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.1% | -5.2% | 6th lowest of 21 |
| 6-month return | -35.8% | -10.4% | 4th lowest of 21 |
| Distance from 52-week high | -53.8% | -36.7% | 3rd lowest of 21 |
| Operating margin | -838.1% | -7.4% | lowest of 16 |
| EV / Sales | 39.3× | 6.3× | 2nd most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics RAPP | United States | $1.17B | -36% | n/a | -838% | 39.3× | n/a | n/a |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.14B | -10% | -24% | -2% | 3.2× | 16.4% | -5.8% |
| UroGen Pharma URGN | United States | $1.21B | -16% | +159% | -12% | 5.2× | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.22B | -13% | n/a | n/a | n/a | n/a | n/a |
| Vor Biopharma VOR | United States | $1.22B | +17% | n/a | n/a | n/a | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.22B | +34% | +18% | 10% | 2.1× | 15.8% | +9.9% |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.23B | -60% | -5% | -181% | 7.0× | n/a | n/a |
| SpyGlass Pharma SGP | United States | $1.24B | +58% | n/a | n/a | n/a | n/a | n/a |
| Daan Gene 002030.SZ | China | $1.11B | -9% | +1% | -81% | 8.4× | 5.7% | -32.3% |
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |
| Janux Therapeutics JANX | United States | $1.08B | +24% | +5,367% | -598% | 5.3× | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.28B | -10% | -9% | 0% | 2.5× | 8.8% | -7.0% |
| Verastem VSTM | United States | $1.02B | +72% | +3,996% | -183% | 11.1× | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $1.02B | -4% | -28% | 11% | 16.3× | 42.9% | -16.6% |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $1.00B | -11% | +2% | -29% | 10.0× | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 3.8× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $995M | -11% | 0% | 22% | 4.7× | 11.1% | +2.3% |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | 429.8× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 6.3× | -1.2% | +25.6% |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 10.3× | 36.5% | -13.1% |